| Cash flow (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | 7.09B | 7.40B | 6.64B | 5.58B | 5.66B | 2.76B | 4.41B | 970.30M |
| Depreciation and amortization | 534.00M | 509.00M | 585.70M | 470.30M | 478.00M | 463.00M | 485.20M | 466.80M |
| Stock-based compensation | 201.00M | 161.00M | 136.10M | 150.90M | 185.00M | 154.00M | 142.30M | 133.20M |
| Cash from operations | 10.69B | 5.33B | 3.22B | 8.84B | 3.09B | 1.67B | 2.47B | 3.71B |
| Cash from investing | -15.40B | -3.92B | -2.80B | -2.98B | -1.83B | -3.35B | -1.92B | -4.00B |
| Dividends paid | -1.55B | -1.55B | -1.35B | -1.35B | -1.35B | -1.35B | -1.17B | -1.17B |
| Share buybacks | -1.60B | -2.36B | -1.51B | -708.30M | -692.00M | -1.20B | -2.05B | -446.10M |
| Net debt issued | 8.07B | -750.00M | -100.0K | 6.71B | -778.00M | 6.46B | 100.0K | 4.96B |
| Cash from financing | 8.43B | -3.47B | -2.88B | 530.80M | -1.25B | 1.38B | -225.50M | 211.30M |
| Net change in cash | 3.67B | -1.99B | -2.52B | 6.42B | 283.00M | -175.00M | -101.40M | 145.40M |
From Eli Lilly's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.